;" target="_blank" title="CleanGredients®">CleanGredients® is an online database of quality cleaning product ingredients. It helps formulators identify the ingredients they need to help them formulate greener, more sustainable cleaning products. CleanGredients® is a project of nonprofit institute GreenBlue®.
"We're excited to be the first solvent listed in CleanGredients®," said David Wood, product director -- DuPont Tate & Lyle Bio Products. "We share similar objectives with GreenBlue® around quality, sustainability and minimizing our environmental footprint. We believe this listing will enable more formulators to take advantage of the performance benefits of Zemea® and help them to streamline the process for achieving DfE recognition for their cleaning products."
DfE is one of the EPA's premier partnership programs, working with industry sectors to compare and improve the human health and environmental risks - as well as the performance and cost - of existing and alternative products, processes and practices. The DfE provides screens for safer chemicals to identify preferred ingredients. NSF International provides third party reviews for the U.S. EPA DfE formulator program. NSF International is the world leader in standards development, product certification, education and risk-management for public health and safety.
DuPont Tate & Lyle Bio Products is a joint venture between DuPont, a global science company, and Tate & Lyle, a world-leading renewable food and industrial ingredients company. DuPont Tate & Lyle Bio Products provides natural and renewably sourced ingredients that do not compromise product performance. For more information on the company's products, visit
Source: PRWeb Copyright©2008 Vocus, Inc. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Zemea Propanediol Approved as a Natural Ingredient by ECOCERT2.
Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery3.
Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C4.
Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing5.
EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial6.
VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer7.
Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial8.
Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo9.
Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone10.
The Science of Music Meets the Art of Medicine - ARIMM 3rd Annual Conference at IPFW, September 12-13, 200811.
Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients